Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Best

Showing results (321-330 of 503) with videos related to

Pageof 51
Sort By:
Diabetic Medicine : a Journal of the British Diabetic Association|October 31, 1998
Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizabilityD N O'Neal, R C O'Brien, K L Timmins, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 31, 2006
In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the ratJonathan D Best, Mark T Jay, Franklin Otu, et al.
Frontiers in Microbiology|February 13, 2026
Genomic analysis of non-carbapenem drug-resistant Gram-negative bacteria from advanced chronic liver disease (ACLD) patients suggests no evidence for in-house transmissionsChristopher D Best, Zahra Nemati, Tilman Schultze, et al.
Trials|August 30, 2012
Scaling-up from an implementation trial to state-wide coverage: results from the preliminary Melbourne Diabetes Prevention StudyEdward D Janus, James D Best, Nathalie Davis-Lameloise, et al.
Diabetes Care|March 21, 2012
Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohortJames D Best, Paul L Drury, Timothy M E Davis, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
Leaflet specific phospholipid imaging using genetically encoded proximity sensorsWilliam M Moore, Roberto J Brea, Caroline Knittel, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 24, 2005
Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal functionCraig L Nelson, Connie S Karschimkus, George Dragicevic, et al.
Diabetes Research and Clinical Practice|April 2, 2013
The metabolic syndrome and CVD outcomes for a central Australian cohortJoanne N Luke, Alex Brown, Mark Daniel, et al.
Epigenomics|March 22, 2018
Transient epigenomic changes during pregnancy and early postpartum in women with and without type 2 diabetesAgnes A Michalczyk, Edward D Janus, Alisha Judge, et al.
Diabetes Research and Clinical Practice|November 12, 2013
Response to the Letter by Kawada et al. regarding the manuscript entitled "The metabolic syndrome and CVD outcomes for a central Australian cohort"Joanne N Luke, Alex Brown, Mark Daniel, et al.
Pageof 51

Showing results (321-330 of 503) with videos related to

Sort By:
Pageof 51
Diabetic Medicine : a Journal of the British Diabetic Association|October 31, 1998
Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizabilityD N O'Neal, R C O'Brien, K L Timmins, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 31, 2006
In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the ratJonathan D Best, Mark T Jay, Franklin Otu, et al.
Frontiers in Microbiology|February 13, 2026
Genomic analysis of non-carbapenem drug-resistant Gram-negative bacteria from advanced chronic liver disease (ACLD) patients suggests no evidence for in-house transmissionsChristopher D Best, Zahra Nemati, Tilman Schultze, et al.
Trials|August 30, 2012
Scaling-up from an implementation trial to state-wide coverage: results from the preliminary Melbourne Diabetes Prevention StudyEdward D Janus, James D Best, Nathalie Davis-Lameloise, et al.
Diabetes Care|March 21, 2012
Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohortJames D Best, Paul L Drury, Timothy M E Davis, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
Leaflet specific phospholipid imaging using genetically encoded proximity sensorsWilliam M Moore, Roberto J Brea, Caroline Knittel, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 24, 2005
Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal functionCraig L Nelson, Connie S Karschimkus, George Dragicevic, et al.
Diabetes Research and Clinical Practice|April 2, 2013
The metabolic syndrome and CVD outcomes for a central Australian cohortJoanne N Luke, Alex Brown, Mark Daniel, et al.
Epigenomics|March 22, 2018
Transient epigenomic changes during pregnancy and early postpartum in women with and without type 2 diabetesAgnes A Michalczyk, Edward D Janus, Alisha Judge, et al.
Diabetes Research and Clinical Practice|November 12, 2013
Response to the Letter by Kawada et al. regarding the manuscript entitled "The metabolic syndrome and CVD outcomes for a central Australian cohort"Joanne N Luke, Alex Brown, Mark Daniel, et al.
Pageof 51